Related Experiment Video
Updated: Jun 1, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wolfgang Wick1, Michael Weller, Markus Weiler
1Department of Neurooncology, National Center of Tumor Disease, University Clinic Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de
Abstract:
Insights into the molecular pathogenesis of glioblastoma have not yet resulted in relevant clinical improvement. With standard therapy, which consists of surgical resection with concomitant temozolomide in addition to radiotherapy followed by adjuvant temozolomide, the median duration of survival is 12-14 months. Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblastoma treatment. Recent results of bevacizumab may represent a proof of principle that treatment with targeted agents can result in clinical benefits for patients with glioblastoma. This review discusses limitations in the existing therapy for glioblastoma and provides an overview of current efforts to identify molecular targets using large-scale screening of glioblastoma cell lines and tumor samples. We discuss preclinical and clinical data for several novel molecular targets, including growth factor receptors, phosphatidylinositol-3 kinase, SRC-family kinases, integrins, and CD95 ligand and agents that inhibit these targets, including erlotinib, enzastaurin, dasatinib, sorafenib, cilengitide, AMG102, and APG101. By combining advances in tumor screening with novel targeted therapies, it is hoped that new treatment options will emerge for this challenging tumor type.
Insights
Glioblastoma treatment faces challenges, but novel molecular targets and targeted therapies show promise. Research focuses on identifying new agents to improve patient survival beyond current standards.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Standard glioblastoma therapy (surgery, temozolomide, radiotherapy) offers limited survival benefits (12-14 months).
- Existing treatments have not significantly improved outcomes despite insights into molecular pathogenesis.
- Bevacizumab's success suggests targeted agents can benefit glioblastoma patients.
Purpose of the Study:
- To review limitations of current glioblastoma therapy.
- To explore novel molecular targets and inhibitory agents for glioblastoma treatment.
- To discuss preclinical and clinical data for emerging targeted therapies.
Main Methods:
- Review of existing literature on glioblastoma therapy.
- Analysis of large-scale screening data from glioblastoma cell lines and tumor samples.
- Discussion of preclinical and clinical data for targeted agents.
Main Results:
- Identified limitations in current glioblastoma treatment strategies.
- Highlighted several novel molecular targets: growth factor receptors, phosphatidylinositol-3 kinase, SRC-family kinases, integrins, and CD95 ligand.
- Summarized data for targeted agents including erlotinib, enzastaurin, dasatinib, sorafenib, cilengitide, AMG102, and APG101.
Conclusions:
- Novel molecular targets and targeted therapies are crucial for advancing glioblastoma treatment.
- Combining advanced screening with targeted therapies may yield new treatment options.
- Further research and clinical trials are needed to develop effective targeted treatments for glioblastoma.
